Formosa Pharmaceuticals News
Harrow Acquires U.S. Commercial Rights to BYQLOVI (Clobetasol Propionate Ophthalmic Nanosuspension) 0.05% from Formosa Pharmaceuticals
Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow …
Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain
Formosa Pharmaceuticals and Adalvo Limited Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Ocular Inflammation and Pain TAIPEI – May 28, …
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico
Formosa Pharmaceuticals Announces Licensing Agreement with Apotex Inc., for Commercialization of Clobetasol Propionate Ophthalmic Suspension for Post-Ocular Surgery Inflammation and Pain for Mexico TAIPEI – …
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors
Formosa Pharmaceuticals and Almac Discovery Announce Licensing Agreement for ALM-401, a First-in-Class Bispecific ADC targeting EGFR/ROR1 for the Treatment of Solid Tumors TAIPEI – May …
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain
Formosa Pharmaceuticals and Saval Corporation Announce Licensing Agreement for Clobetasol Propionate Ophthalmic Suspension for the Treatment of Post-Operative Inflammation and Pain TAIPEI – April 26, …
Cipla and Formosa sign their first multi-regional licensing deal for Clobetasol Suspension
Cipla and Formosa sign multi-regional licensing deal for Clobetasol Suspension This partnership aims to enhance ophthalmic care by providing better treatment for post-operative inflammation and …
